LncRNA GAS5 affects epithelial-mesenchymal transition and invasion of breast cancer cells by regulating miR-216b

OBJECTIVE: To study the mechanism of lncRNA GAS5 affecting epithelial-mesenchymal transition and invasion of breast cancer cells by regulating miR-216b. PATIENTS AND METHODS: Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) was used to detect the expressions of GAS5 and miR-216b in breast...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Y. Li [verfasserIn] X.-B. Guo [verfasserIn] Y.-H. Wei [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2020

Übergeordnetes Werk:	In: European Review for Medical and Pharmacological Sciences - Verduci Editore, 2021, 24(2020)
Übergeordnetes Werk:	volume:24 ; year:2020

Links:	Link aufrufen Link aufrufen Journal toc

Katalog-ID:	DOAJ085402788

Internformat


LEADER	01000naa a22002652 4500
001	DOAJ085402788
003	DE-627
005	20230311035001.0
007	cr uuu---uuuuu
008	230311s2020 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)DOAJ085402788
035			\|a (DE-599)DOAJ2cdd53c5d8d744b4877ab51ca4e5e811
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RM1-950
100	0		\|a Y. Li \|e verfasserin \|4 aut
245	1	0	\|a LncRNA GAS5 affects epithelial-mesenchymal transition and invasion of breast cancer cells by regulating miR-216b
264		1	\|c 2020
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a OBJECTIVE: To study the mechanism of lncRNA GAS5 affecting epithelial-mesenchymal transition and invasion of breast cancer cells by regulating miR-216b. PATIENTS AND METHODS: Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) was used to detect the expressions of GAS5 and miR-216b in breast cancer and paracancerous tissues. The relationship between GAS5 and clinicopathological parameters of breast cancer patients was analyzed. The Dual-Luciferase reporter gene was used to detect the interaction between GAS5 and miR-216b and the transwell invasion assay was used to detect the invasive ability of lung cancer cells after GAS5 inhibition. Apoptosis assay was used to detect the apoptosis of breast cancer cells after GAS5 inhibition. Western blotting and immunofluorescence staining were used to detect the inhibition of GAS5 epithelial-mesenchymal transition. RESULTS: Compared with paracancerous tissues, in breast cancer tissues, the expression of GAS5 was increased and the expression of miR-216b was decreased. As the patients enter the later stages of breast cancer, the expression level of GAS5 in breast cancer patients was significantly elevated. The expression of GAS5 in the tissues with lymph node metastasis of breast cancer was markedly increased. The inhibition of GAS5 can promote the apoptosis of breast cancer cells; GAS5 can specifically bind to the 3’ UTR of miR-216b. The expression of GAS5 inhibited the expression of E-cadherin in breast cancer cells and significantly upregulated N-cadherin, which has been confirmed by immunofluorescence staining experiments. CONCLUSIONS: GAS5 plays an important role in the development of breast cancer. GAS5 can target on miR-216b to regulate the biological behavior and epithelial-mesenchymal transition of breast cancer cells.
653		0	\|a Therapeutics. Pharmacology
700	0		\|a X.-B. Guo \|e verfasserin \|4 aut
700	0		\|a Y.-H. Wei \|e verfasserin \|4 aut
773	0	8	\|i In \|t European Review for Medical and Pharmacological Sciences \|d Verduci Editore, 2021 \|g 24(2020) \|w (DE-627)65427049X \|w (DE-600)2598628-4 \|x 22840729 \|7 nnns
773	1	8	\|g volume:24 \|g year:2020
856	4	0	\|u https://doaj.org/article/2cdd53c5d8d744b4877ab51ca4e5e811 \|z kostenfrei
856	4	0	\|u https://www.europeanreview.org/wp/wp-content/uploads/4873-4881-2.pdf \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1128-3602 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 24 \|j 2020

Indexfelder

author_variant	y l yl x b g xbg y h w yhw
matchkey_str	article:22840729:2020----::nraa5feteihlamsnhmlrniinnivsoobescne
hierarchy_sort_str	2020
callnumber-subject-code	RM
publishDate	2020
allfields	(DE-627)DOAJ085402788 (DE-599)DOAJ2cdd53c5d8d744b4877ab51ca4e5e811 DE-627 ger DE-627 rakwb eng RM1-950 Y. Li verfasserin aut LncRNA GAS5 affects epithelial-mesenchymal transition and invasion of breast cancer cells by regulating miR-216b 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier OBJECTIVE: To study the mechanism of lncRNA GAS5 affecting epithelial-mesenchymal transition and invasion of breast cancer cells by regulating miR-216b. PATIENTS AND METHODS: Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) was used to detect the expressions of GAS5 and miR-216b in breast cancer and paracancerous tissues. The relationship between GAS5 and clinicopathological parameters of breast cancer patients was analyzed. The Dual-Luciferase reporter gene was used to detect the interaction between GAS5 and miR-216b and the transwell invasion assay was used to detect the invasive ability of lung cancer cells after GAS5 inhibition. Apoptosis assay was used to detect the apoptosis of breast cancer cells after GAS5 inhibition. Western blotting and immunofluorescence staining were used to detect the inhibition of GAS5 epithelial-mesenchymal transition. RESULTS: Compared with paracancerous tissues, in breast cancer tissues, the expression of GAS5 was increased and the expression of miR-216b was decreased. As the patients enter the later stages of breast cancer, the expression level of GAS5 in breast cancer patients was significantly elevated. The expression of GAS5 in the tissues with lymph node metastasis of breast cancer was markedly increased. The inhibition of GAS5 can promote the apoptosis of breast cancer cells; GAS5 can specifically bind to the 3’ UTR of miR-216b. The expression of GAS5 inhibited the expression of E-cadherin in breast cancer cells and significantly upregulated N-cadherin, which has been confirmed by immunofluorescence staining experiments. CONCLUSIONS: GAS5 plays an important role in the development of breast cancer. GAS5 can target on miR-216b to regulate the biological behavior and epithelial-mesenchymal transition of breast cancer cells. Therapeutics. Pharmacology X.-B. Guo verfasserin aut Y.-H. Wei verfasserin aut In European Review for Medical and Pharmacological Sciences Verduci Editore, 2021 24(2020) (DE-627)65427049X (DE-600)2598628-4 22840729 nnns volume:24 year:2020 https://doaj.org/article/2cdd53c5d8d744b4877ab51ca4e5e811 kostenfrei https://www.europeanreview.org/wp/wp-content/uploads/4873-4881-2.pdf kostenfrei https://doaj.org/toc/1128-3602 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2153 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 24 2020
spelling	(DE-627)DOAJ085402788 (DE-599)DOAJ2cdd53c5d8d744b4877ab51ca4e5e811 DE-627 ger DE-627 rakwb eng RM1-950 Y. Li verfasserin aut LncRNA GAS5 affects epithelial-mesenchymal transition and invasion of breast cancer cells by regulating miR-216b 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier OBJECTIVE: To study the mechanism of lncRNA GAS5 affecting epithelial-mesenchymal transition and invasion of breast cancer cells by regulating miR-216b. PATIENTS AND METHODS: Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) was used to detect the expressions of GAS5 and miR-216b in breast cancer and paracancerous tissues. The relationship between GAS5 and clinicopathological parameters of breast cancer patients was analyzed. The Dual-Luciferase reporter gene was used to detect the interaction between GAS5 and miR-216b and the transwell invasion assay was used to detect the invasive ability of lung cancer cells after GAS5 inhibition. Apoptosis assay was used to detect the apoptosis of breast cancer cells after GAS5 inhibition. Western blotting and immunofluorescence staining were used to detect the inhibition of GAS5 epithelial-mesenchymal transition. RESULTS: Compared with paracancerous tissues, in breast cancer tissues, the expression of GAS5 was increased and the expression of miR-216b was decreased. As the patients enter the later stages of breast cancer, the expression level of GAS5 in breast cancer patients was significantly elevated. The expression of GAS5 in the tissues with lymph node metastasis of breast cancer was markedly increased. The inhibition of GAS5 can promote the apoptosis of breast cancer cells; GAS5 can specifically bind to the 3’ UTR of miR-216b. The expression of GAS5 inhibited the expression of E-cadherin in breast cancer cells and significantly upregulated N-cadherin, which has been confirmed by immunofluorescence staining experiments. CONCLUSIONS: GAS5 plays an important role in the development of breast cancer. GAS5 can target on miR-216b to regulate the biological behavior and epithelial-mesenchymal transition of breast cancer cells. Therapeutics. Pharmacology X.-B. Guo verfasserin aut Y.-H. Wei verfasserin aut In European Review for Medical and Pharmacological Sciences Verduci Editore, 2021 24(2020) (DE-627)65427049X (DE-600)2598628-4 22840729 nnns volume:24 year:2020 https://doaj.org/article/2cdd53c5d8d744b4877ab51ca4e5e811 kostenfrei https://www.europeanreview.org/wp/wp-content/uploads/4873-4881-2.pdf kostenfrei https://doaj.org/toc/1128-3602 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2153 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 24 2020
allfields_unstemmed	(DE-627)DOAJ085402788 (DE-599)DOAJ2cdd53c5d8d744b4877ab51ca4e5e811 DE-627 ger DE-627 rakwb eng RM1-950 Y. Li verfasserin aut LncRNA GAS5 affects epithelial-mesenchymal transition and invasion of breast cancer cells by regulating miR-216b 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier OBJECTIVE: To study the mechanism of lncRNA GAS5 affecting epithelial-mesenchymal transition and invasion of breast cancer cells by regulating miR-216b. PATIENTS AND METHODS: Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) was used to detect the expressions of GAS5 and miR-216b in breast cancer and paracancerous tissues. The relationship between GAS5 and clinicopathological parameters of breast cancer patients was analyzed. The Dual-Luciferase reporter gene was used to detect the interaction between GAS5 and miR-216b and the transwell invasion assay was used to detect the invasive ability of lung cancer cells after GAS5 inhibition. Apoptosis assay was used to detect the apoptosis of breast cancer cells after GAS5 inhibition. Western blotting and immunofluorescence staining were used to detect the inhibition of GAS5 epithelial-mesenchymal transition. RESULTS: Compared with paracancerous tissues, in breast cancer tissues, the expression of GAS5 was increased and the expression of miR-216b was decreased. As the patients enter the later stages of breast cancer, the expression level of GAS5 in breast cancer patients was significantly elevated. The expression of GAS5 in the tissues with lymph node metastasis of breast cancer was markedly increased. The inhibition of GAS5 can promote the apoptosis of breast cancer cells; GAS5 can specifically bind to the 3’ UTR of miR-216b. The expression of GAS5 inhibited the expression of E-cadherin in breast cancer cells and significantly upregulated N-cadherin, which has been confirmed by immunofluorescence staining experiments. CONCLUSIONS: GAS5 plays an important role in the development of breast cancer. GAS5 can target on miR-216b to regulate the biological behavior and epithelial-mesenchymal transition of breast cancer cells. Therapeutics. Pharmacology X.-B. Guo verfasserin aut Y.-H. Wei verfasserin aut In European Review for Medical and Pharmacological Sciences Verduci Editore, 2021 24(2020) (DE-627)65427049X (DE-600)2598628-4 22840729 nnns volume:24 year:2020 https://doaj.org/article/2cdd53c5d8d744b4877ab51ca4e5e811 kostenfrei https://www.europeanreview.org/wp/wp-content/uploads/4873-4881-2.pdf kostenfrei https://doaj.org/toc/1128-3602 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2153 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 24 2020
allfieldsGer	(DE-627)DOAJ085402788 (DE-599)DOAJ2cdd53c5d8d744b4877ab51ca4e5e811 DE-627 ger DE-627 rakwb eng RM1-950 Y. Li verfasserin aut LncRNA GAS5 affects epithelial-mesenchymal transition and invasion of breast cancer cells by regulating miR-216b 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier OBJECTIVE: To study the mechanism of lncRNA GAS5 affecting epithelial-mesenchymal transition and invasion of breast cancer cells by regulating miR-216b. PATIENTS AND METHODS: Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) was used to detect the expressions of GAS5 and miR-216b in breast cancer and paracancerous tissues. The relationship between GAS5 and clinicopathological parameters of breast cancer patients was analyzed. The Dual-Luciferase reporter gene was used to detect the interaction between GAS5 and miR-216b and the transwell invasion assay was used to detect the invasive ability of lung cancer cells after GAS5 inhibition. Apoptosis assay was used to detect the apoptosis of breast cancer cells after GAS5 inhibition. Western blotting and immunofluorescence staining were used to detect the inhibition of GAS5 epithelial-mesenchymal transition. RESULTS: Compared with paracancerous tissues, in breast cancer tissues, the expression of GAS5 was increased and the expression of miR-216b was decreased. As the patients enter the later stages of breast cancer, the expression level of GAS5 in breast cancer patients was significantly elevated. The expression of GAS5 in the tissues with lymph node metastasis of breast cancer was markedly increased. The inhibition of GAS5 can promote the apoptosis of breast cancer cells; GAS5 can specifically bind to the 3’ UTR of miR-216b. The expression of GAS5 inhibited the expression of E-cadherin in breast cancer cells and significantly upregulated N-cadherin, which has been confirmed by immunofluorescence staining experiments. CONCLUSIONS: GAS5 plays an important role in the development of breast cancer. GAS5 can target on miR-216b to regulate the biological behavior and epithelial-mesenchymal transition of breast cancer cells. Therapeutics. Pharmacology X.-B. Guo verfasserin aut Y.-H. Wei verfasserin aut In European Review for Medical and Pharmacological Sciences Verduci Editore, 2021 24(2020) (DE-627)65427049X (DE-600)2598628-4 22840729 nnns volume:24 year:2020 https://doaj.org/article/2cdd53c5d8d744b4877ab51ca4e5e811 kostenfrei https://www.europeanreview.org/wp/wp-content/uploads/4873-4881-2.pdf kostenfrei https://doaj.org/toc/1128-3602 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2153 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 24 2020
allfieldsSound	(DE-627)DOAJ085402788 (DE-599)DOAJ2cdd53c5d8d744b4877ab51ca4e5e811 DE-627 ger DE-627 rakwb eng RM1-950 Y. Li verfasserin aut LncRNA GAS5 affects epithelial-mesenchymal transition and invasion of breast cancer cells by regulating miR-216b 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier OBJECTIVE: To study the mechanism of lncRNA GAS5 affecting epithelial-mesenchymal transition and invasion of breast cancer cells by regulating miR-216b. PATIENTS AND METHODS: Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) was used to detect the expressions of GAS5 and miR-216b in breast cancer and paracancerous tissues. The relationship between GAS5 and clinicopathological parameters of breast cancer patients was analyzed. The Dual-Luciferase reporter gene was used to detect the interaction between GAS5 and miR-216b and the transwell invasion assay was used to detect the invasive ability of lung cancer cells after GAS5 inhibition. Apoptosis assay was used to detect the apoptosis of breast cancer cells after GAS5 inhibition. Western blotting and immunofluorescence staining were used to detect the inhibition of GAS5 epithelial-mesenchymal transition. RESULTS: Compared with paracancerous tissues, in breast cancer tissues, the expression of GAS5 was increased and the expression of miR-216b was decreased. As the patients enter the later stages of breast cancer, the expression level of GAS5 in breast cancer patients was significantly elevated. The expression of GAS5 in the tissues with lymph node metastasis of breast cancer was markedly increased. The inhibition of GAS5 can promote the apoptosis of breast cancer cells; GAS5 can specifically bind to the 3’ UTR of miR-216b. The expression of GAS5 inhibited the expression of E-cadherin in breast cancer cells and significantly upregulated N-cadherin, which has been confirmed by immunofluorescence staining experiments. CONCLUSIONS: GAS5 plays an important role in the development of breast cancer. GAS5 can target on miR-216b to regulate the biological behavior and epithelial-mesenchymal transition of breast cancer cells. Therapeutics. Pharmacology X.-B. Guo verfasserin aut Y.-H. Wei verfasserin aut In European Review for Medical and Pharmacological Sciences Verduci Editore, 2021 24(2020) (DE-627)65427049X (DE-600)2598628-4 22840729 nnns volume:24 year:2020 https://doaj.org/article/2cdd53c5d8d744b4877ab51ca4e5e811 kostenfrei https://www.europeanreview.org/wp/wp-content/uploads/4873-4881-2.pdf kostenfrei https://doaj.org/toc/1128-3602 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2153 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 24 2020
language	English
source	In European Review for Medical and Pharmacological Sciences 24(2020) volume:24 year:2020
sourceStr	In European Review for Medical and Pharmacological Sciences 24(2020) volume:24 year:2020
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Therapeutics. Pharmacology
isfreeaccess_bool	true
container_title	European Review for Medical and Pharmacological Sciences
authorswithroles_txt_mv	Y. Li @@aut@@ X.-B. Guo @@aut@@ Y.-H. Wei @@aut@@
publishDateDaySort_date	2020-01-01T00:00:00Z
hierarchy_top_id	65427049X
id	DOAJ085402788
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ085402788</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230311035001.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230311s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ085402788</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ2cdd53c5d8d744b4877ab51ca4e5e811</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Y. Li</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">LncRNA GAS5 affects epithelial-mesenchymal transition and invasion of breast cancer cells by regulating miR-216b</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">OBJECTIVE: To study the mechanism of lncRNA GAS5 affecting epithelial-mesenchymal transition and invasion of breast cancer cells by regulating miR-216b. PATIENTS AND METHODS: Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) was used to detect the expressions of GAS5 and miR-216b in breast cancer and paracancerous tissues. The relationship between GAS5 and clinicopathological parameters of breast cancer patients was analyzed. The Dual-Luciferase reporter gene was used to detect the interaction between GAS5 and miR-216b and the transwell invasion assay was used to detect the invasive ability of lung cancer cells after GAS5 inhibition. Apoptosis assay was used to detect the apoptosis of breast cancer cells after GAS5 inhibition. Western blotting and immunofluorescence staining were used to detect the inhibition of GAS5 epithelial-mesenchymal transition. RESULTS: Compared with paracancerous tissues, in breast cancer tissues, the expression of GAS5 was increased and the expression of miR-216b was decreased. As the patients enter the later stages of breast cancer, the expression level of GAS5 in breast cancer patients was significantly elevated. The expression of GAS5 in the tissues with lymph node metastasis of breast cancer was markedly increased. The inhibition of GAS5 can promote the apoptosis of breast cancer cells; GAS5 can specifically bind to the 3’ UTR of miR-216b. The expression of GAS5 inhibited the expression of E-cadherin in breast cancer cells and significantly upregulated N-cadherin, which has been confirmed by immunofluorescence staining experiments. CONCLUSIONS: GAS5 plays an important role in the development of breast cancer. GAS5 can target on miR-216b to regulate the biological behavior and epithelial-mesenchymal transition of breast cancer cells.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">X.-B. Guo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Y.-H. Wei</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">European Review for Medical and Pharmacological Sciences</subfield><subfield code="d">Verduci Editore, 2021</subfield><subfield code="g">24(2020)</subfield><subfield code="w">(DE-627)65427049X</subfield><subfield code="w">(DE-600)2598628-4</subfield><subfield code="x">22840729</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:24</subfield><subfield code="g">year:2020</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/2cdd53c5d8d744b4877ab51ca4e5e811</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.europeanreview.org/wp/wp-content/uploads/4873-4881-2.pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1128-3602</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">24</subfield><subfield code="j">2020</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Y. Li
spellingShingle	Y. Li misc RM1-950 misc Therapeutics. Pharmacology LncRNA GAS5 affects epithelial-mesenchymal transition and invasion of breast cancer cells by regulating miR-216b
authorStr	Y. Li
ppnlink_with_tag_str_mv	@@773@@(DE-627)65427049X
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RM1-950
illustrated	Not Illustrated
issn	22840729
topic_title	RM1-950 LncRNA GAS5 affects epithelial-mesenchymal transition and invasion of breast cancer cells by regulating miR-216b
topic	misc RM1-950 misc Therapeutics. Pharmacology
topic_unstemmed	misc RM1-950 misc Therapeutics. Pharmacology
topic_browse	misc RM1-950 misc Therapeutics. Pharmacology
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	European Review for Medical and Pharmacological Sciences
hierarchy_parent_id	65427049X
hierarchy_top_title	European Review for Medical and Pharmacological Sciences
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)65427049X (DE-600)2598628-4
title	LncRNA GAS5 affects epithelial-mesenchymal transition and invasion of breast cancer cells by regulating miR-216b
ctrlnum	(DE-627)DOAJ085402788 (DE-599)DOAJ2cdd53c5d8d744b4877ab51ca4e5e811
title_full	LncRNA GAS5 affects epithelial-mesenchymal transition and invasion of breast cancer cells by regulating miR-216b
author_sort	Y. Li
journal	European Review for Medical and Pharmacological Sciences
journalStr	European Review for Medical and Pharmacological Sciences
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2020
contenttype_str_mv	txt
author_browse	Y. Li X.-B. Guo Y.-H. Wei
container_volume	24
class	RM1-950
format_se	Elektronische Aufsätze
author-letter	Y. Li
author2-role	verfasserin
title_sort	lncrna gas5 affects epithelial-mesenchymal transition and invasion of breast cancer cells by regulating mir-216b
callnumber	RM1-950
title_auth	LncRNA GAS5 affects epithelial-mesenchymal transition and invasion of breast cancer cells by regulating miR-216b
abstract	OBJECTIVE: To study the mechanism of lncRNA GAS5 affecting epithelial-mesenchymal transition and invasion of breast cancer cells by regulating miR-216b. PATIENTS AND METHODS: Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) was used to detect the expressions of GAS5 and miR-216b in breast cancer and paracancerous tissues. The relationship between GAS5 and clinicopathological parameters of breast cancer patients was analyzed. The Dual-Luciferase reporter gene was used to detect the interaction between GAS5 and miR-216b and the transwell invasion assay was used to detect the invasive ability of lung cancer cells after GAS5 inhibition. Apoptosis assay was used to detect the apoptosis of breast cancer cells after GAS5 inhibition. Western blotting and immunofluorescence staining were used to detect the inhibition of GAS5 epithelial-mesenchymal transition. RESULTS: Compared with paracancerous tissues, in breast cancer tissues, the expression of GAS5 was increased and the expression of miR-216b was decreased. As the patients enter the later stages of breast cancer, the expression level of GAS5 in breast cancer patients was significantly elevated. The expression of GAS5 in the tissues with lymph node metastasis of breast cancer was markedly increased. The inhibition of GAS5 can promote the apoptosis of breast cancer cells; GAS5 can specifically bind to the 3’ UTR of miR-216b. The expression of GAS5 inhibited the expression of E-cadherin in breast cancer cells and significantly upregulated N-cadherin, which has been confirmed by immunofluorescence staining experiments. CONCLUSIONS: GAS5 plays an important role in the development of breast cancer. GAS5 can target on miR-216b to regulate the biological behavior and epithelial-mesenchymal transition of breast cancer cells.
abstractGer	OBJECTIVE: To study the mechanism of lncRNA GAS5 affecting epithelial-mesenchymal transition and invasion of breast cancer cells by regulating miR-216b. PATIENTS AND METHODS: Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) was used to detect the expressions of GAS5 and miR-216b in breast cancer and paracancerous tissues. The relationship between GAS5 and clinicopathological parameters of breast cancer patients was analyzed. The Dual-Luciferase reporter gene was used to detect the interaction between GAS5 and miR-216b and the transwell invasion assay was used to detect the invasive ability of lung cancer cells after GAS5 inhibition. Apoptosis assay was used to detect the apoptosis of breast cancer cells after GAS5 inhibition. Western blotting and immunofluorescence staining were used to detect the inhibition of GAS5 epithelial-mesenchymal transition. RESULTS: Compared with paracancerous tissues, in breast cancer tissues, the expression of GAS5 was increased and the expression of miR-216b was decreased. As the patients enter the later stages of breast cancer, the expression level of GAS5 in breast cancer patients was significantly elevated. The expression of GAS5 in the tissues with lymph node metastasis of breast cancer was markedly increased. The inhibition of GAS5 can promote the apoptosis of breast cancer cells; GAS5 can specifically bind to the 3’ UTR of miR-216b. The expression of GAS5 inhibited the expression of E-cadherin in breast cancer cells and significantly upregulated N-cadherin, which has been confirmed by immunofluorescence staining experiments. CONCLUSIONS: GAS5 plays an important role in the development of breast cancer. GAS5 can target on miR-216b to regulate the biological behavior and epithelial-mesenchymal transition of breast cancer cells.
abstract_unstemmed	OBJECTIVE: To study the mechanism of lncRNA GAS5 affecting epithelial-mesenchymal transition and invasion of breast cancer cells by regulating miR-216b. PATIENTS AND METHODS: Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) was used to detect the expressions of GAS5 and miR-216b in breast cancer and paracancerous tissues. The relationship between GAS5 and clinicopathological parameters of breast cancer patients was analyzed. The Dual-Luciferase reporter gene was used to detect the interaction between GAS5 and miR-216b and the transwell invasion assay was used to detect the invasive ability of lung cancer cells after GAS5 inhibition. Apoptosis assay was used to detect the apoptosis of breast cancer cells after GAS5 inhibition. Western blotting and immunofluorescence staining were used to detect the inhibition of GAS5 epithelial-mesenchymal transition. RESULTS: Compared with paracancerous tissues, in breast cancer tissues, the expression of GAS5 was increased and the expression of miR-216b was decreased. As the patients enter the later stages of breast cancer, the expression level of GAS5 in breast cancer patients was significantly elevated. The expression of GAS5 in the tissues with lymph node metastasis of breast cancer was markedly increased. The inhibition of GAS5 can promote the apoptosis of breast cancer cells; GAS5 can specifically bind to the 3’ UTR of miR-216b. The expression of GAS5 inhibited the expression of E-cadherin in breast cancer cells and significantly upregulated N-cadherin, which has been confirmed by immunofluorescence staining experiments. CONCLUSIONS: GAS5 plays an important role in the development of breast cancer. GAS5 can target on miR-216b to regulate the biological behavior and epithelial-mesenchymal transition of breast cancer cells.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2153 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
title_short	LncRNA GAS5 affects epithelial-mesenchymal transition and invasion of breast cancer cells by regulating miR-216b
url	https://doaj.org/article/2cdd53c5d8d744b4877ab51ca4e5e811 https://www.europeanreview.org/wp/wp-content/uploads/4873-4881-2.pdf https://doaj.org/toc/1128-3602
remote_bool	true
author2	X.-B. Guo Y.-H. Wei
author2Str	X.-B. Guo Y.-H. Wei
ppnlink	65427049X
callnumber-subject	RM - Therapeutics and Pharmacology
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
callnumber-a	RM1-950
up_date	2024-07-03T14:32:26.330Z
_version_	1803568699239563264
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ085402788</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230311035001.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230311s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ085402788</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ2cdd53c5d8d744b4877ab51ca4e5e811</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Y. Li</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">LncRNA GAS5 affects epithelial-mesenchymal transition and invasion of breast cancer cells by regulating miR-216b</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">OBJECTIVE: To study the mechanism of lncRNA GAS5 affecting epithelial-mesenchymal transition and invasion of breast cancer cells by regulating miR-216b. PATIENTS AND METHODS: Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) was used to detect the expressions of GAS5 and miR-216b in breast cancer and paracancerous tissues. The relationship between GAS5 and clinicopathological parameters of breast cancer patients was analyzed. The Dual-Luciferase reporter gene was used to detect the interaction between GAS5 and miR-216b and the transwell invasion assay was used to detect the invasive ability of lung cancer cells after GAS5 inhibition. Apoptosis assay was used to detect the apoptosis of breast cancer cells after GAS5 inhibition. Western blotting and immunofluorescence staining were used to detect the inhibition of GAS5 epithelial-mesenchymal transition. RESULTS: Compared with paracancerous tissues, in breast cancer tissues, the expression of GAS5 was increased and the expression of miR-216b was decreased. As the patients enter the later stages of breast cancer, the expression level of GAS5 in breast cancer patients was significantly elevated. The expression of GAS5 in the tissues with lymph node metastasis of breast cancer was markedly increased. The inhibition of GAS5 can promote the apoptosis of breast cancer cells; GAS5 can specifically bind to the 3’ UTR of miR-216b. The expression of GAS5 inhibited the expression of E-cadherin in breast cancer cells and significantly upregulated N-cadherin, which has been confirmed by immunofluorescence staining experiments. CONCLUSIONS: GAS5 plays an important role in the development of breast cancer. GAS5 can target on miR-216b to regulate the biological behavior and epithelial-mesenchymal transition of breast cancer cells.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">X.-B. Guo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Y.-H. Wei</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">European Review for Medical and Pharmacological Sciences</subfield><subfield code="d">Verduci Editore, 2021</subfield><subfield code="g">24(2020)</subfield><subfield code="w">(DE-627)65427049X</subfield><subfield code="w">(DE-600)2598628-4</subfield><subfield code="x">22840729</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:24</subfield><subfield code="g">year:2020</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/2cdd53c5d8d744b4877ab51ca4e5e811</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.europeanreview.org/wp/wp-content/uploads/4873-4881-2.pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1128-3602</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">24</subfield><subfield code="j">2020</subfield></datafield></record></collection>
score	7.3997183

Nicht das Richtige dabei?

Schreiben Sie uns!

LncRNA GAS5 affects epithelial-mesenchymal transition and invasion of breast cancer cells by regulating miR-216b

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?